BioCentury
ARTICLE | Company News

ODAC to discuss Aveo, Delcath cancer compounds

February 27, 2013 1:44 AM UTC

FDA's Oncologic Drugs Advisory Committee will meet on May 2 to discuss NDAs for two cancer compounds from Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) and Delcath Systems Inc. (NASDAQ:DCTH). The committee will discuss Aveo's Tivopath tivozanib to treat advanced renal cell carcinoma (RCC), which has a July 28 PDUFA date. Aveo, which is partnered with Astellas Pharma Inc. (Tokyo:4503) for tivozanib, has exclusive ex-Asian rights to the inhibitor of VEGF receptors 1, 2 and 3 from Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151). On Tuesday, Aveo was up $0.04 to $6.55. ...